H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Neurocrine Biosciences to $146 from $140 and keeps a Buy rating on the shares after the company announced the approval of Ingrezza for chorea associated with Huntington’s disease. This expands Ingrezza’s presence to an additional neurological condition with a clear unmet need, the analyst tells investors in a research note. Given the superior efficacy profile and a differentiated label, Ingrezza has considerable potential to grow, says the firm.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine Stock (NASDAQ:NBIX): Investors and Analysts are Bullish
- Neurocrine announces FDA approval of Ingrezza
- Neurocrine price target raised to $132 from $130 at Canaccord
- Neurocrine price target raised to $135 from $127 at Cantor Fitzgerald
- Neurocrine price target raised to $125 from $120 at TD Cowen